Advanced Pulmonary Sarcoidosis.

At least 5% of sarcoidosis patients die from their disease, usually from advanced pulmonary sarcoidosis. The three major problems encountered in advanced pulmonary sarcoidosis are pulmonary fibrosis, pulmonary hypertension, and respiratory infections. Pulmonary fibrosis is the result of chronic inflammation, but other factors including abnormal wound healing may be important. Sarcoidosis-associated pulmonary hypertension (SAPH) is multifactorial including parenchymal fibrosis, vascular granulomas, and hypoxia. Respiratory infections can be cause by structural changes in the lung and impaired immunity due to sarcoidosis or therapy. Anti-inflammatory therapy alone is not effective in most forms of advanced pulmonary sarcoidosis. New techniques, including high-resolution computer tomography and 18F-fluorodeoxyglucose positron emission tomography (PET) have proved helpful in identifying the cause of advanced disease and directing specific therapy.

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

R.P.B. reports grants from Bayer, Genentech, aTyr, grants and personal fees from Mallinckrodt, grants from Novartis, Gilead, personal fees from KinBio, during the conduct of the study, grants from Foundation for Sarcoidosis research, National Institutes of Health, outside the submitted work.